PROGENICS PHARMACEUTICALS IN's ticker is PGNX and the CUSIP is 743187106. A total of 133 filers reported holding PROGENICS PHARMACEUTICALS IN in Q3 2015. The put-call ratio across all filers is 1.52 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2020 | $1,288,000 | -15.9% | 338,888 | +12.7% | 0.00% | – |
| Q4 2019 | $1,531,000 | +68.6% | 300,768 | +67.5% | 0.00% | – |
| Q3 2019 | $908,000 | +32.2% | 179,586 | +61.3% | 0.00% | – |
| Q2 2019 | $687,000 | -55.9% | 111,355 | -66.8% | 0.00% | – |
| Q1 2019 | $1,557,000 | +25.3% | 335,729 | +13.5% | 0.00% | – |
| Q4 2018 | $1,243,000 | -37.6% | 295,761 | -6.9% | 0.00% | -100.0% |
| Q3 2018 | $1,992,000 | -41.8% | 317,741 | -25.3% | 0.00% | 0.0% |
| Q2 2018 | $3,421,000 | +104.7% | 425,510 | +90.0% | 0.00% | – |
| Q1 2018 | $1,671,000 | +13.2% | 224,007 | -9.7% | 0.00% | – |
| Q4 2017 | $1,476,000 | -7.1% | 247,970 | +14.9% | 0.00% | – |
| Q3 2017 | $1,588,000 | -25.3% | 215,728 | -31.1% | 0.00% | -100.0% |
| Q2 2017 | $2,125,000 | -73.0% | 313,006 | -62.5% | 0.00% | -50.0% |
| Q1 2017 | $7,880,000 | +236.2% | 834,742 | +207.8% | 0.00% | +100.0% |
| Q4 2016 | $2,344,000 | -60.6% | 271,208 | -71.2% | 0.00% | -50.0% |
| Q3 2016 | $5,952,000 | +2668.4% | 940,338 | +1748.0% | 0.00% | – |
| Q2 2016 | $215,000 | +138.9% | 50,884 | +147.2% | 0.00% | – |
| Q1 2016 | $90,000 | -89.9% | 20,585 | -85.8% | 0.00% | – |
| Q4 2015 | $891,000 | -14.8% | 145,450 | -20.5% | 0.00% | – |
| Q3 2015 | $1,046,000 | -13.7% | 182,910 | +12.6% | 0.00% | – |
| Q2 2015 | $1,212,000 | +140.5% | 162,453 | +92.9% | 0.00% | – |
| Q1 2015 | $504,000 | +13.8% | 84,237 | +43.7% | 0.00% | – |
| Q4 2014 | $443,000 | +74.4% | 58,620 | +19.8% | 0.00% | – |
| Q3 2014 | $254,000 | -0.4% | 48,924 | -17.4% | 0.00% | – |
| Q2 2014 | $255,000 | -7.9% | 59,258 | -12.4% | 0.00% | – |
| Q1 2014 | $277,000 | -54.3% | 67,610 | -40.5% | 0.00% | – |
| Q4 2013 | $606,000 | +40.3% | 113,720 | +32.1% | 0.00% | – |
| Q3 2013 | $432,000 | -75.4% | 86,084 | -78.1% | 0.00% | -100.0% |
| Q2 2013 | $1,754,000 | +59.3% | 393,352 | +6.5% | 0.00% | – |
| Q4 2012 | $1,101,000 | +49.8% | 369,352 | +44.7% | 0.00% | – |
| Q3 2012 | $735,000 | -72.2% | 255,297 | -5.6% | 0.00% | -100.0% |
| Q2 2012 | $2,644,000 | +6.5% | 270,361 | +7.8% | 0.00% | 0.0% |
| Q1 2012 | $2,483,000 | – | 250,763 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARDSLEY ADVISORY PARTNERS LP | 1,255,000 | $5,823,000 | 1.12% |
| Phocas Financial Corp. | 1,146,292 | $5,319,000 | 0.54% |
| Worth Venture Partners, LLC | 138,357 | $641,000 | 0.36% |
| RICE HALL JAMES & ASSOCIATES, LLC | 2,293,179 | $10,640,000 | 0.34% |
| Monashee Investment Management LLC | 240,000 | $1,114,000 | 0.26% |
| BKS ADVISORS, LLC | 118,587 | $550,000 | 0.22% |
| PINNACLE ASSOCIATES LTD | 1,418,391 | $6,581,000 | 0.15% |
| FARALLON CAPITAL MANAGEMENT LLC | 4,200,820 | $19,492,000 | 0.15% |
| Fosun International Ltd | 472,580 | $2,174,000 | 0.14% |
| CARILLON TOWER ADVISERS, INC. | 3,948,024 | $18,318,000 | 0.13% |